• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

疾病持续时间作为评估利拉鲁肽治疗 2 型糖尿病患者疗效的指标。

Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.

机构信息

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Department of Internal Medicine, Slingeland Hospital, Doetinchem, the Netherlands.

出版信息

J Diabetes Investig. 2018 Jul;9(4):979-980. doi: 10.1111/jdi.12857.

DOI:10.1111/jdi.12857
PMID:29974671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6031510/
Abstract

Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).

摘要

评论 Usui 等人的文章。一项对 69 例 2 型糖尿病肥胖患者的回顾性队列研究表明，利拉鲁肽作为胰岛素的附加疗法降低血糖的效果依赖于 2 型糖尿病患者β细胞的剩余功能。疾病持续时间越短，用利拉鲁肽瞬时替代胰岛素的反应预后越好（HR 2.39（95%CI：1.20-4.76））。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc8/6031510/a6144614f107/JDI-9-979-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc8/6031510/a6144614f107/JDI-9-979-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc8/6031510/a6144614f107/JDI-9-979-g001.jpg

相似文献

1
Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.疾病持续时间作为评估利拉鲁肽治疗 2 型糖尿病患者疗效的指标。
J Diabetes Investig. 2018 Jul;9(4):979-980. doi: 10.1111/jdi.12857.
2
Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.回复 Wilbrink 等人对利拉鲁肽和基础胰岛素联合治疗日本 2 型糖尿病的回顾性分析的评论：起始治疗 1 年后，剩余β细胞功能与 HbA1c 达标之间的关系。
J Diabetes Investig. 2018 Jul;9(4):981-983. doi: 10.1111/jdi.12858.
3
Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.利拉鲁肽单药治疗与磺脲类药物联合治疗对日本2型糖尿病患者安全性和有效性的回顾性分析：起始治疗一年后剩余β细胞功能与糖化血红蛋白（HbA1c）目标达成情况的关联
J Diabetes Complications. 2015 Nov-Dec;29(8):1203-10. doi: 10.1016/j.jdiacomp.2015.07.020. Epub 2015 Jul 21.
4
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.利拉鲁肽或甘精胰岛素治疗可改善 26 周内肥胖 2 型糖尿病和非酒精性脂肪性肝病患者的肝脂肪：一项随机安慰剂对照试验。
Diabetes Res Clin Pract. 2020 Dec;170:108487. doi: 10.1016/j.diabres.2020.108487. Epub 2020 Oct 6.
5
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.胰岛素甘精胰岛素滴定上调与胰岛素德谷胰岛素/利拉鲁肽对血糖控制不佳的 2 型糖尿病患者糖化血红蛋白水平的影响：DUAL V 随机临床试验。
JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252.
6
Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.在意大利真实临床环境中接受利拉鲁肽治疗的大量糖尿病患者中，基线特征与临床结局之间的相关性。
Clin Ther. 2015 Mar 1;37(3):574-84. doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24.
7
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.在一项 3 期、开放标签、随机试验中，与胰岛素德谷胰岛素和利拉鲁肽相比，胰岛素德谷胰岛素和利拉鲁肽固定比例组合（IDegLira）在日本 2 型糖尿病胰岛素初治患者中显示出更高的疗效。
Diabetes Obes Metab. 2019 Dec;21(12):2674-2683. doi: 10.1111/dom.13856. Epub 2019 Aug 28.
8
Predictors of response to liraglutide in Japanese type 2 diabetes.日本2型糖尿病患者对利拉鲁肽反应的预测因素
Diabetes Res Clin Pract. 2014 Dec;106(3):451-7. doi: 10.1016/j.diabres.2014.09.052. Epub 2014 Oct 7.
9
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.利拉鲁肽，一种胰高血糖素样肽-1（GLP-1）类似物，对日本肥胖 2 型糖尿病患者的体重、饮食行为和血糖控制的疗效。
Cardiovasc Diabetol. 2012 Sep 14;11:107. doi: 10.1186/1475-2840-11-107.
10
Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.利拉鲁肽作为胰岛素的附加治疗用于肥胖 1 型糖尿病患者。
Endocr Pract. 2013 Nov-Dec;19(6):963-7. doi: 10.4158/EP13065.OR.

引用本文的文献

1
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.替尔泊肽治疗2型糖尿病患者的疗效和安全性：SURPASS-AP-Combo不同亚组分析
Diabetes Ther. 2024 May;15(5):1125-1137. doi: 10.1007/s13300-024-01561-2. Epub 2024 Mar 18.
2
Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.利拉鲁肽与生活方式改变对肥胖的前驱糖尿病或 2 型糖尿病患者在体重减轻相当后可溶性肿瘤抑制物 2（sST2）和半乳糖凝集素-3 的影响。
Cardiovasc Diabetol. 2022 Mar 11;21(1):36. doi: 10.1186/s12933-022-01469-w.
3

本文引用的文献

1
Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.回顾性分析利拉鲁肽与基础胰岛素联合治疗日本 2 型糖尿病患者：起始治疗 1 年后糖化血红蛋白达标与残余β细胞功能的相关性。
J Diabetes Investig. 2018 Jul;9(4):822-830. doi: 10.1111/jdi.12773. Epub 2017 Dec 13.
Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.
回复 Wilbrink 等人对利拉鲁肽和基础胰岛素联合治疗日本 2 型糖尿病的回顾性分析的评论：起始治疗 1 年后，剩余β细胞功能与 HbA1c 达标之间的关系。
J Diabetes Investig. 2018 Jul;9(4):981-983. doi: 10.1111/jdi.12858.